Context Therapeutics
CNTX
37 hedge funds and large institutions have $66.8M invested in Context Therapeutics in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 7 closing their positions.
49% more capital invested
Capital invested by funds: $45M → $66.8M (+$21.9M)
0.39% more ownership
Funds ownership: 76.5% → 76.88% (+0.39%)
5% less funds holding
Funds holding: 39 → 37 (-2)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$1.22M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$109K |
| 3 |
Pathstone Holdings
Englewood,
New Jersey
|
+$89.4K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$83.8K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$29K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$446K |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$222K |
| 3 |
LM
Luminus Management
Houston,
Texas
|
-$215K |
| 4 |
AAA
Affinity Asset Advisors
New York
|
-$93.5K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$38.2K |
CNTX Hedge Fund Activity: Q3 2025 in Review
37 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Context Therapeutics (CNTX) for Q3 2025, worth a combined $66.8M — up 49% from $45M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CNTX and 6 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 6 added.
The largest buyer was Avidity Partners Management, adding an estimated $1.22M. The largest seller was Woodline Partners, exiting entirely with an estimated $446K sold.
- 37 institutional investors held Context Therapeutics (CNTX) as of Q3 2025, down from 39 in Q2 2025.
- Funds reported $66.8M of Context Therapeutics stock for Q3 2025, up 49% quarter-over-quarter.
- 6 funds opened new Context Therapeutics positions in Q3 2025 and 7 closed out, a net change of -1 holder.
- The largest Context Therapeutics buyer in Q3 2025 was Avidity Partners Management, an estimated $1.22M added.
- The largest Context Therapeutics seller in Q3 2025 was Woodline Partners, an estimated $446K sold.
Based on aggregated 13F filings for Q3 2025.